


**In the claims:**

1. (Presently amended) A compound of Formula I:



wherein:

R<sup>1a</sup> and R<sup>1b</sup> are independently selected from:

- 1) hydrogen,
- 2) unsubstituted or substituted C<sub>1</sub>-C<sub>10</sub> alkyl,
- 3) OR<sup>3</sup>,
- 4) N(R<sup>3</sup>)<sub>2</sub>,
- 5) unsubstituted or substituted aryl,
- 6) unsubstituted or substituted heterocycle, and
- 7) unsubstituted or substituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl;

R<sup>1c</sup> is independently selected from:

- 1) hydrogen,
- 2) C<sub>1</sub>-C<sub>10</sub> alkyl,
- 3) OR<sup>3</sup>,
- 4) N(R<sup>3</sup>)<sub>2</sub>,
- 5) C<sub>3</sub>-C<sub>10</sub> cycloalkyl,
- 6) aryl, and
- 7) heterocycle;

said alkyl, cycloalkyl, aryl and heterocycle is optionally substituted with at least one substituent selected from R<sup>7</sup>;

R<sup>2</sup> is independently selected from:

- 1) ~~hydrogen,~~
- 2) ~~unsubstituted or substituted C<sub>1</sub>-C<sub>10</sub> alkyl,~~
- 3) N(R<sup>3</sup>)<sub>2</sub>, and
- 4) OR<sup>3</sup>;
- 5) ~~unsubstituted or substituted aryl, and~~
- 6) ~~unsubstituted or substituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl;~~

R<sup>3</sup> is independently selected from:

- 1) hydrogen, and
- 2) C<sub>1</sub>-C<sub>10</sub> alkyl;
- 3) ~~aryl,~~
- 4) ~~heterocycle,~~
- 5) ~~C<sub>3</sub>-C<sub>10</sub> cycloalkyl,~~
- 6) ~~CF<sub>3</sub>;~~
- 7) ~~C<sub>2</sub>-C<sub>6</sub> alkenyl,~~
- 8) ~~C<sub>2</sub>-C<sub>6</sub> alkynyl,~~
- 9) ~~S(O)<sub>m</sub>R<sup>6</sup>, and~~
- 10) C(O)R<sup>6</sup>;

said alkyl, cycloalkyl, aryl, heterocycle, alkynyl, and alkenyl is optionally substituted with at least one substituent selected from R<sup>7</sup>;

R<sup>5</sup> is independently selected from:

- 1) hydrogen,
- 2) halogen,
- 3) -(CR<sup>1</sup>c<sub>2</sub>)<sub>n</sub>OR<sup>3</sup>,
- 4) -(CR<sup>1</sup>c<sub>2</sub>)<sub>n</sub>R<sup>6</sup>,
- 5) -C(O)OR<sup>3</sup>,
- 6) -C(O)R<sup>3</sup>,
- 7) -C≡CR<sup>3</sup>,
- 8) -R<sup>3</sup>C=C(R<sup>3</sup>)<sub>2</sub>,
- 9) -OS(O)<sub>m</sub>R<sup>6</sup>,
- 10) -NO<sub>2</sub>,

- 11)  $-(\text{CR}^1\text{c}_2)_n\text{N}(\text{R}^3)_2$ ,
- 12)  $-\text{N}(\text{R}^3)\text{C}(\text{O})\text{R}^3$ ,
- 13)  $-\text{N}(\text{R}^3)\text{S}(\text{O})_m\text{R}^6$ ,
- 14)  $-(\text{CR}^1\text{c}_2)_n\text{NR}^3(\text{CR}^1\text{c}_2)_n\text{C}(\text{O})\text{NR}^3_2$ ,
- 15)  $-\text{O}(\text{CR}^1\text{c}_2)_n\text{C}(\text{O})\text{N}(\text{R}^3)_2$ ,
- 16)  $-\text{O}(\text{CR}^1\text{c}_2)_n\text{C}(\text{O})\text{OR}^3$ ,
- 17)  $-\text{NR}^3(\text{CR}^1\text{c}_2)_n\text{N}(\text{R}^3)_2$ ,
- 18)  $-(\text{CR}^1\text{c}_2)_n\text{NR}^3\text{R}^6\text{OR}^3$ ,
- 19)  $-\text{S}(\text{O})_m\text{R}^6$ ,
- 20)  $-\text{S}(\text{O})_m\text{N}(\text{R}^3)_2$ ,
- 21)  $-\text{CN}$ ,
- 22)  $-(\text{CR}^1\text{c}_2)_n\text{N}(\text{R}^3)(\text{CR}^1\text{c}_2)_n\text{R}^6$ , and
- 23)  $-(\text{CR}^1\text{c}_2)_n\text{C}(\text{O})\text{N}(\text{R}^3)_2$ ;

R<sup>6</sup> is independently selected from:

- 1) C<sub>1</sub>-C<sub>10</sub> alkyl,
- 2) C<sub>3</sub>-C<sub>10</sub> cycloalkyl,
- 3) aryl, and
- 4) heterocycle;

said, alkyl, cycloalkyl, aryl and heterocycle is optionally substituted with at least one substituent selected from R<sup>7</sup>;

R<sup>7</sup> is independently selected from:

- 1) hydrogen,
- 2) unsubstituted or substituted C<sub>1</sub>-C<sub>10</sub> alkyl,
- 3) unsubstituted or substituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl,
- 4) unsubstituted or substituted aryl,
- 5) halogen,
- 6) OR<sup>3</sup>,
- 7) CF<sub>3</sub>,
- 8) unsubstituted or substituted heterocycle,
- 9) S(O)<sub>m</sub>N(R<sup>3</sup>)<sub>2</sub>,
- 10) C(O)OR<sup>3</sup>,
- 11) C(O)R<sup>3</sup>,

- 12) CN,
- 13) C(O)N(R<sup>3</sup>)<sub>2</sub>,
- 14) N(R<sup>3</sup>)C(O)R<sup>3</sup>,
- 15) S(O)<sub>m</sub>R<sup>6</sup>, and
- 16) NO<sub>2</sub>;

Y and Z are independently selected from:

- 1) hydrogen,
- 2) R<sup>6</sup>,
- 3) OR<sup>3</sup>,
- 4) N(R<sup>3</sup>)<sub>2</sub>,
- 5) C(O)OR<sup>3</sup>,
- 6) C(O)N(R<sup>3</sup>)<sub>2</sub>,
- 7) C(O)R<sup>3</sup>,
- 8) halogen,
- 9) N(R<sup>3</sup>)(CR<sup>1c2</sup>)<sub>n</sub>C(O)N(R<sup>3</sup>)<sub>2</sub>,
- 10) S(O)<sub>m</sub>N(R<sup>3</sup>)<sub>2</sub>,
- 11) N(R<sup>3</sup>)C(O)OR<sup>3</sup>,
- 12) N(R<sup>3</sup>)S(O)<sub>m</sub>R<sup>6</sup>,
- 13) N(R<sup>3</sup>)C(O)R<sup>3</sup>,
- 14) N(R<sup>3</sup>)(CR<sup>1c2</sup>)<sub>n</sub>R<sup>3</sup>,
- 15) S(O)<sub>m</sub>R<sup>6</sup>,
- 16) R<sup>6</sup>S(O)<sub>m</sub>N(R<sup>3</sup>)<sub>2</sub>,
- 17) R<sup>6</sup>S(O)<sub>m</sub>R<sup>6</sup>,
- 18) N(R<sup>3</sup>) S(O)<sub>m</sub> (CR<sup>1c2</sup>)<sub>n</sub>R<sup>6</sup>,
- 19) N(R<sup>3</sup>)S(O)<sub>m</sub>R<sup>6</sup>OR<sup>3</sup>,
- 20) N(R<sup>3</sup>)C(O)N(R<sup>3</sup>)<sub>2</sub>,
- 21) N(R<sup>3</sup>)C(O)R<sup>6</sup>OR<sup>3</sup>,
- 22) N(R<sup>3</sup>)(CR<sup>1c2</sup>)<sub>n</sub>R<sup>6</sup>OR<sup>3</sup>,
- 23) N(R<sup>3</sup>)OR<sup>3</sup>, and
- 24) N(R<sup>3</sup>)S(O)<sub>m</sub>R<sup>6</sup>NO<sub>2</sub>;

m is independently 0, 1 or 2;

n is independently 0 to 6;

s is 0 to 6;

t is 0 to 6;

w is 0 to 4;

or a pharmaceutically acceptable salt or stereoisomer thereof.

2. (Presently amended) The compound according to Claim 1,  
wherein:

R<sup>1a</sup> and R<sup>1b</sup> are independently selected from:

- 1) hydrogen,
- 2) unsubstituted or substituted C<sub>1</sub>-C<sub>10</sub> alkyl,
- 3) unsubstituted or substituted aryl,
- 4) unsubstituted or substituted heterocycle, and
- 5) OR<sup>3</sup>;

R<sup>1c</sup> is independently selected from:

- 1) hydrogen,
- 2) C<sub>1</sub>-C<sub>10</sub> alkyl,
- 3) OR<sup>3</sup>,
- 4) N(R<sup>3</sup>)<sub>2</sub>,
- 5) aryl, and
- 6) heterocycle;

said alkyl, aryl and heterocycle is optionally substituted with at least one substituent selected from R<sup>7</sup>;

R<sup>2</sup> is:

- 1) —H,
- 2) ~~unsubstituted or substituted alkyl,~~
- 3) OR<sup>3</sup>, or
- 4) N(R<sup>3</sup>)<sub>2</sub>;

R<sup>3</sup> is independently selected from:

- 1) hydrogen, and

- 2) C<sub>1</sub>-C<sub>10</sub> alkyl;
- 3) ~~aryl~~;
- 4) ~~heterocycle~~;
- 5) ~~C<sub>3</sub>-C<sub>10</sub> cycloalkyl~~;
- 6) ~~CF<sub>3</sub>~~;
- 7) ~~S(O)<sub>m</sub>R<sup>6</sup>~~; and
- 8) C(O)R<sup>6</sup>;

said alkyl, ~~cycloalkyl~~, ~~aryl~~ and ~~heterocycle~~ is optionally substituted with at least one substituent selected from R<sup>7</sup>;

R<sup>5</sup> is independently selected from:

- 1) hydrogen,
- 2) halogen,
- 3) -OR<sup>3</sup>,
- 4) -C(O)OR<sup>3</sup>,
- 5) -C(O)R<sup>3</sup>,
- 6) -C≡CR<sup>3</sup>,
- 7) -R<sup>3</sup>C=C(R<sup>3</sup>)<sub>2</sub>,
- 8) -OS(O)<sub>m</sub>R<sup>6</sup>,
- 9) -NO<sub>2</sub>,
- 10) -N(R<sup>3</sup>)<sub>2</sub>,
- 11) -N(R<sup>3</sup>)C(O)R<sup>3</sup>,
- 12) -N(R<sup>3</sup>)S(O)<sub>m</sub>R<sup>6</sup>,
- 13) -(CR<sup>1</sup>c<sub>2</sub>)<sub>n</sub>NR<sup>3</sup>(CR<sup>1</sup>c<sub>2</sub>)<sub>n</sub>C(O)NR<sup>3</sup><sub>2</sub>,
- 14) -O(CR<sup>1</sup>c<sub>2</sub>)<sub>n</sub>C(O)N(R<sup>3</sup>)<sub>2</sub>,
- 15) -O(CR<sup>1</sup>c<sub>2</sub>)<sub>n</sub>C(O)OR<sup>3</sup>,
- 16) -NR<sup>3</sup>(CR<sup>1</sup>c<sub>2</sub>)<sub>n</sub>N(R<sup>3</sup>)<sub>2</sub>,
- 17) -(CR<sup>1</sup>c<sub>2</sub>)<sub>n</sub>NR<sup>3</sup>R<sup>6</sup>OR<sup>3</sup>,
- 18) -S(O)<sub>m</sub>R<sup>6</sup>,
- 19) -S(O)<sub>m</sub>N(R<sup>3</sup>)<sub>2</sub>,
- 20) -CN, and
- 21) -(CR<sup>1</sup>c<sub>2</sub>)<sub>n</sub>N(R<sup>3</sup>)(CR<sup>1</sup>c<sub>2</sub>)<sub>n</sub>R<sup>6</sup>;

or a pharmaceutically acceptable salt or stereoisomer thereof.

3. (Original) The compound according to Claim 2,

wherein:

R<sup>1a</sup> and R<sup>1b</sup> are independently selected from hydrogen, unsubstituted or substituted C<sub>1</sub>-C<sub>10</sub> alkyl, OR<sup>3</sup>, and unsubstituted or substituted aryl;

R<sup>1c</sup> is independently selected from:

- 1) hydrogen,
- 2) C<sub>1</sub>-C<sub>10</sub> alkyl,
- 3) OR<sup>3</sup>, and
- 4) aryl;

said alkyl and aryl is optionally substituted with at least one substituent selected from R<sup>7</sup>;

R<sup>2</sup> is:

- 1) OR<sup>3</sup>, or
- 2) N(R<sup>3</sup>)<sub>2</sub>;

R<sup>5</sup> is independently selected from:

- 1) hydrogen,
- 2) (CR<sup>1c2</sup>)<sub>n</sub>R<sup>6</sup>,
- 3) halogen,
- 4) -(CR<sup>1c2</sup>)<sub>n</sub>OR<sup>3</sup>,
- 5) -C(O)OR<sup>3</sup>,
- 6) -C(O)R<sup>3</sup>,
- 7) -C≡CR<sup>3</sup>,
- 8) -R<sup>3</sup>C=C(R<sup>3</sup>)<sub>2</sub>,
- 9) (CR<sup>1c2</sup>)<sub>n</sub>C(O)N(R<sup>3</sup>)<sub>2</sub>, and
- 10) (CR<sup>1c2</sup>)<sub>n</sub>N(R<sup>3</sup>)<sub>2</sub>;

Y is:

- 1) hydrogen,
- 2) R<sup>6</sup>,
- 3) OR<sup>3</sup>,
- 4) C(O)R<sup>3</sup>,

- 5)  $C(O)N(R^3)_2$ , or
- 6)  $N(R^3)_2$ ;

Z is:

- 1) hydrogen,
- 2)  $R^6$ ,
- 3)  $OR^3$ ,
- 4)  $N(R^3)_2$ ,
- 5)  $C(O)OR^3$ ,
- 6)  $C(O)N(R^3)_2$ ,
- 7)  $C(O)R^3$ ,
- 8) halogen,
- 9)  $N(R^3)(CR^{1c_2})_n C(O)N(R^3)_2$ ,
- 10)  $S(O)_m N(R^3)_2$ ,
- 11)  $N(R^3)C(O)OR^3$ ,
- 12)  $N(R^3)S(O)_m R^6$ ,
- 13)  $N(R^3)C(O)R^3$ ,
- 14)  $N(R^3)(CR^{1c_2})_n R^3$ , or
- 15)  $S(O)_m R^6$ ;

n is independently 0 to 4;

or a pharmaceutically acceptable salt or stereoisomer thereof.

4. (Presently amended) A compound selected from:

5-Chloro-3-[(methylamino)sulfonyl]-1*H*-indole-2-carboxamide;

3-(Aminosulfonyl)-5-chloro-1*H*-indole-2-carboxamide;

5-Bromo-3-({methyl[(5-oxo-4,5-dihydro-1*H*-1,2,4-triazol-3 yl)methyl] amino}  
sulfonyl)-1*H*-indole-2-carboxamide;

3-({[2-(Aminosulfonyl)ethyl]amino} sulfonyl)-5-iodo-1*H*-indole-2-carboxamide;

3-[(Dimethylamino)sulfonyl]-5-methoxy-1*H*-indole-2-carboxamide;



5-Chloro-3- {[ (2-phenethyl)amino]sulfonyl} -1*H*-indole-2-carboxamide;  
5-Chloro-3- [(benzylamino)sulfonyl]-1*H*-indole-2-carboxamide;  
5-Chloro-3- [(cyclohexylamino)sulfonyl]-1*H*-indole-2-carboxamide;  
5-Chloro-3- [(1-naphthylamino)sulfonyl]-1*H*-indole-2-carboxamide;  
5-Chloro-3- {[ (3-phenylpropyl)amino]sulfonyl} -1*H*-indole-2-carboxamide;  
5-Chloro-3- [(ethylamino)sulfonyl]-1*H*-indole-2-carboxamide;  
5-Chloro-3- [(propylamino)sulfonyl]-1*H*-indole-2-carboxamide;  
5-Chloro-3- [(butylamino)sulfonyl]-1*H*-indole-2-carboxamide;  
5-Chloro-3- [(pentylamino)sulfonyl]-1*H*-indole-2-carboxamide;  
5-Chloro-3- {[ ethyl(methyl)amino]sulfonyl} -1*H*-indole-2-carboxamide;  
5-Chloro-3- [(diethylamino)sulfonyl]-1*H*-indole-2-carboxamide;  
5-Chloro-3- [(*iso*-propylamino)sulfonyl]-1*H*-indole-2-carboxamide;  
5-Chloro-3- [(cyclobutylamino)sulfonyl]-1*H*-indole-2-carboxamide;  
5-Chloro-3- [(cyclopentylamino)sulfonyl]-1*H*-indole-2-carboxamide;  
5-Chloro-3- {[ (4-chlorophenyl)amino} sulfonyl]-1*H*-indole-2-carboxamide;  
5-Chloro-3- {[ (3-chlorophenyl)amino} sulfonyl]-1*H*-indole-2-carboxamide;  
5-Chloro-3- {[ (2-chlorophenyl)amino} sulfonyl]-1*H*-indole-2-carboxamide;  
5-Chloro-3- {[ (4-chlorophenyl)methylamino} sulfonyl]-1*H*-indole-2-carboxamide;  
5-Chloro-3- {[ (3-chlorophenyl)methylamino} sulfonyl]-1*H*-indole-2-carboxamide;  
5-Chloro-3- {[ (2-chlorophenyl)methylamino} sulfonyl]-1*H*-indole-2-carboxamide;  
5-Chloro-3- [(*tert*-butylamino)sulfonyl]-1*H*-indole-2-carboxamide;

(±)-5-Chloro-3-[(pyrrolidin-3-ylamino)sulfonyl]-1*H*-indole-2-carboxamide;  
5-Chloro-3-[(piperidin-4-ylamino)sulfonyl]-1*H*-indole-2-carboxamide;  
5-Chloro-3-[[[(1-methyl-1*H*-benzimidazol-2-yl)amino]sulfonyl]-1*H*-indole-2-carboxamide;  
5-Chloro-3-[(benzamideamino)sulfonyl]-1*H*-indole-2-carboxamide;  
5-Chloro-3-[(5-aminotetrazole)sulfonyl]-1*H*-indole-2-carboxamide;  
5-Chloro-3-[(pyridin-4-ylamino)sulfonyl]-1*H*-indole-2-carboxamide;  
5-Chloro-3-[(pyridin-2-ylamino)sulfonyl]-1*H*-indole-2-carboxamide;  
5-Chloro-3-[[[(2-methoxyethyl)amino]sulfonyl]-1*H*-indole-2-carboxamide;  
5-Chloro-3-[(dimethylamino)sulfonyl]-1*H*-indole-2-carboxamide;  
3-([2-(Aminosulfonyl)ethyl]amino)sulfonyl]-5-chloro-1*H*-indole-2-carboxamide;  
5-Chloro-3-[[[(2-hydroxyethyl)amino]sulfonyl]-1*H*-indole-2-carboxamide;  
5-Chloro-3-[[[(2-morpholin-4-ylethyl)amino]sulfonyl]-1*H*-indole-2-carboxamide;  
5-Chloro-3-[[[(2-methoxyethyl)(methyl)amino]sulfonyl]-1*H*-indole-2-carboxamide;  
5-Bromo-3-([2-([2-(2-acetamide)amino)ethyl]amino)sulfonyl]-1*H*-indole-2-carboxamide;  
*N*-{[2-(Aminocarbonyl)-5-bromo-1*H*-indol-3-yl]sulfonyl}-*N*-methyl-β-alaninamide;  
5-Bromo-3-[(methylamino)sulfonyl]-1*H*-indole-2-carboxamide;  
Ethyl *N*-{[2-(aminocarbonyl)-5-bromo-1*H*-indol-3-yl]sulfonyl} *N*-methyl-β-alaninate;  
5-Bromo-3-[[cyclopropyl(methyl)amino]sulfonyl]-1*H*-indole-2-carboxamide;  
(±)-5-Bromo-3-[[methyl(tetrahydrofuran-3-yl)amino]sulfonyl]-1*H*-indole-2-carboxamide;

5-Bromo-3-({methyl[2-(1*H*-1,2,4-triazol-1-yl)ethyl]amino}sulfonyl)-1*H*-indole-2-carboxamide;

5-Bromo-3-{{methyl(tetrahydro-2*H*-pyran-4-yl)amino}sulfonyl}-1*H*-indole-2-carboxamide;

(±)-5-Bromo-3-{{(1,4-dioxan-2-ylmethyl)(methyl)amino}sulfonyl}-1*H*-indole-2-carboxamide;

3-({[4-(Aminosulfonyl)benzyl]amino}sulfonyl)-5-bromo-1*H*-indole-2-carboxamide;

5-Chloro-3-{{*iso*-propyl(2-methoxyethyl)amino}sulfonyl}-1*H*-indole-2-carboxamide;

3-{{(2-Bromoethyl)(2-hydroxyethyl)amino}sulfonyl}-5-hydroxy-1*H*-indole-2-carboxamide;

3-{{(2-Bromoethyl)(2-hydroxyethyl)amino}sulfonyl}-5-methoxy-1*H*-indole-2-carboxamide;

5-Chloro-3-{{methoxy(methyl)amino}sulfonyl}-1*H*-indole-2-carboxamide;

(±)-5-Chloro-3-{{(2,3-dihydroxypropyl)(methyl)amino}sulfonyl}-1*H*-indole-2-carboxamide;

5-Chloro-3-{{(2-hydroxyethyl)(methyl)amino}sulfonyl}-1*H*-indole-2-carboxamide;

*N*-{{[2-(Aminocarbonyl)-5-chloro-1*H*-indol-3-yl]sulfonyl}-*N*-methylglycine;

*N*-{{[2-(Aminocarbonyl)-5-chloro-1*H*-indol-3-yl]sulfonyl}-*N*-methylglycinamide;

5-Bromo-3-({[4-(methylsulfonyl)benzyl]amino}sulfonyl)-1*H*-indole-2-carboxamide;

3-[(2-[4-(Aminosulfonyl)phenyl]ethyl)amino)sulfonyl]-5-bromo-1*H*-indole-2-carboxamide;

3-{{(5-Amino-5-oxopentyl)amino}sulfonyl}-5-bromo-1*H*-indole-2-carboxamide;

3-({[2-(Aminosulfonyl)ethyl]amino}sulfonyl)-5-bromo-1*H*-indole-2-carboxamide;

*tert*-Butyl 2-({[2-(aminocarbonyl)-5-bromo-1*H*-indol-3-yl]sulfonyl)amino)-ethylcarbamate;

3-{{(2-Aminoethyl)amino}sulfonyl}-5-bromo-1*H*-indole-2-carboxamide;

5-Bromo-3-[(2-({ethylsulfonylamino}ethylamino)sulfonyl)-1*H*-indole-2-carboxamide;

5-Iodo-3-{{(2-{{(4-methoxyphenyl)sulfonyl}amino}ethyl)amino}sulfonyl}-1*H*-indole-2-carboxamide;

5-Bromo-3-{{methoxy(methyl)amino}sulfonyl}-1*H*-indole-2-carboxamide;

5-Fluoro-3- {[ (2- {[ (4-methoxyphenyl)sulfonyl]amino}ethyl)(methyl)amino]sulfonyl} -1*H*-indole-2-carboxamide;

5-Bromo-3- {[ (2- {[ (4-nitrophenyl)sulfonyl]amino}ethyl)amino]sulfonyl} -1*H*-indole-2-carboxamide;

5-Bromo-3- ( {[ (2- ( {[ (4-methoxyphenyl)amino]carbonyl}amino)ethyl]amino}sulfonyl)-1*H*-indole-2-carboxamide;

5-Bromo-3- [ ( {3- [(4-chlorophenyl)thio]propyl}amino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Bromo-3- [ ( {3- [(4-chlorophenyl)thio]propyl}amino)sulfonyl]-1 *H*-indole-2-carboxamide;

5-Bromo-3- [ ( {3- [(4-chlorophenyl)sulfonyl]propyl}amino)sulfonyl]-1 *H*-indole-2-carboxamide;

5-Bromo-3- [ ( {propylsulfonylamino}ethylamino)sulfonyl]-1*H*-indole-2-carboxamide hydrochloride;

5-Bromo-3- {[ (2- {[ (4-methoxyphenyl)sulfonyl]amino}ethyl)amino]sulfonyl} -1*H*-indole-2-carboxamide;

5-Bromo-3- [ ( {2- [(phenylsulfonyl)amino]ethyl}amino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Bromo-3- [ ( {2- [(methylsulfonyl)amino]ethyl}amino)sulfonyl]-1*H*-indole-2-carboxamide;

3- [ ( {2- [(Benzylsulfonyl)amino]ethyl}amino)sulfonyl]-5-bromo-1*H*-indole-2-carboxamide;

5-Bromo-3- {[ (2- {[ (3-methoxyphenyl)sulfonyl]amino}ethyl)amino]sulfonyl} -1*H*-indole-2-carboxamide;

5-Bromo-3- {[ (2- {[ (2,5-dimethoxyphenyl)sulfonyl]amino}ethyl)amino]sulfonyl} -1*H* -indole-2-carboxamide;

5-Bromo-3-[[[2-[[[2-(5-bromo-2-methoxyphenyl)sulfonyl]amino]ethyl]amino] sulfonyl]-1*H*-indole-2-carboxamide;

5-Bromo-3-([2-([2-(trifluoromethoxy)phenyl)sulfonyl]amino)ethyl]amino) sulfonyl)-1 *H*-indole-2-carboxamide;

5-Bromo-3-[[[2-[[[2-methoxy-5-methylphenyl)sulfonyl]amino]ethyl]amino] sulfonyl]-1*H*-indole-2-carboxamide;

5-Bromo-3-[[[2-[[[4-cyanophenyl)sulfonyl]amino]ethyl]amino]sulfonyl]-1*H*-indole-2-carboxamide;

5-Bromo-3-[[[2-[[[4-chlorophenyl)sulfonyl]amino]ethyl]amino]sulfonyl]-1*H*-indole-2-carboxamide;

5-Bromo-3-[[[2-[[[3,4-dimethoxyphenyl)sulfonyl]amino]ethyl]amino]sulfonyl]-1*H*-indole-2-carboxamide;

5-Bromo-3-[(3-[(phenylsulfonyl)amino]propyl)amino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Bromo-3-[[[3-[[[4-methoxyphenyl)sulfonyl]amino]propyl]amino]sulfonyl]-1*H*-indole-2-carboxamide;

3-[(3-[(Benzylsulfonyl)amino]propyl)amino)sulfonyl]-5-bromo-1*H*-indole-2-carboxamide;

3-[(2-[(Aminocarbonyl)amino]ethyl)amino)sulfonyl]-5-bromo-1*H*-indole-2-carboxamide;

5-Bromo-3-[[[2-[[[4-bromophenyl)sulfonyl]amino]ethyl]amino]sulfonyl]-1*H*-indole-2-carboxamide;

5-Bromo-3-[(2-[(thien-3-ylsulfonyl)amino]ethyl)amino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Bromo-3-{{(2-{{(3-chlorobenzyl)sulfonyl}amino}ethyl)amino)sulfonyl}-1*H*-indole-2-carboxamide;

5-Bromo-3-{{(2-{{(2-phenylethyl)sulfonyl}amino}ethyl)amino)sulfonyl}-1*H*-indole-2-carboxamide;

5-Bromo-3-[(2-[(4-methoxybenzoyl)amino]ethyl)amino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Bromo-3-[(2-[(4-methoxybenzyl)amino]ethyl)amino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Bromo-3-[(2-[(4-methoxyphenyl)amino]ethyl)amino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Bromo-3-[(2-[(4-methoxyphenyl)(methylsulfonyl)amino]ethyl)amino)sulfonyl]-1*H*-indole-2-carboxamide;

3-[(2-[Acetyl(4-methoxyphenyl)amino]ethyl)amino)sulfonyl]-5-bromo-1*H*-indole-2-carboxamide;

5-Iodo-3-[[cyclopropyl(methyl)amino]sulfonyl]-1*H*-indole-2-carboxamide;

5-Iodo-3-[(cyclopropylamino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Bromo-3-[(cyclopropylamino)sulfonyl]-1*H*-indole-2-carboxamide;

5-Iodo-3-[[methoxy(methyl)amino]sulfonyl]-1*H*-indole-2-carboxamide;

(±)-5-Chloro-3-[[[(tetrahydro-2*H*-pyran-2-ylmethyl)amino]sulfonyl]-1*H*-indole-2-carboxamide;

(±)-5-Bromo-3-[[[(tetrahydro-2*H*-pyran-2-ylmethyl)amino]sulfonyl]-1*H*-indole-2-carboxamide;

(±)-5-Iodo-3-[[[(tetrahydro-2*H*-pyran-2-ylmethyl)amino]sulfonyl]-1*H*-indole-2-carboxamide;

(±)-5-Chloro-3-[[[methyl(tetrahydro-2*H*-pyran-2-ylmethyl)amino]sulfonyl]-1*H*-indole-2-carboxamide;

(±)-5-Bromo-3- {[methyl(tetrahydro-2*H*-pyran-2-ylmethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

(±)-5-Iodo-3- {[methyl(tetrahydro-2*H*-pyran-2-ylmethyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

5-Bromo-3- ({[2-(tert-butylthio)ethyl]amino} sulfonyl)-1-*H*-indole-2-carboxamide;

5-chloro-3- {[methyl(tetrahydro-2*H*-pyran-4-yl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

5-chloro-3- ({[1-(2,3-dihydro-1,4-benzodioxin-2-yl)ethyl]amino} sulfonyl)-1*H*-indole-2-carboxamide;

5-chloro-3- [(tetrahydro-2*H*-pyran-4-ylamino)sulfonyl]-1*H*-indole-2-carboxamide;

5-chloro-3- {[ (1,4-dioxan-2-ylmethyl)(methyl)amino]sulfonyl}-1*H*-indole-2-carboxamide;

5-chloro-3- ({[(3-methyloxetan-3-yl)methyl]amino} sulfonyl)-1*H*-indole-2-carboxamide;

5-chloro-3- [(tetrahydrofuran-3-ylamino)sulfonyl]-1*H*-indole-2-carboxamide;

5-chloro-3- ({[(1,1-dioxidotetrahydrothien-3-yl)methyl]amino} sulfonyl)-1*H*-indole-2-carboxamide;

5-chloro-3- ({[2-(3-phenyl-1*H*-1,2,4-triazol-5-yl)ethyl]amino} sulfonyl)-1*H*-indole-2-carboxamide;

5-chloro-3- ({[2-(2-methoxyphenyl)ethyl]amino} sulfonyl)-1*H*-indole-2-carboxamide;

5-chloro-3- ({[3-(trifluoromethyl)benzyl]amino} sulfonyl)-1*H*-indole-2-carboxamide;

5-chloro-3- ({[2-(2,3-dihydro-1*H*-indol-1-yl)ethyl]amino} sulfonyl)-1*H*-indole-2-carboxamide;

5-chloro-3- ({methyl[(1-methylpiperidin-3-yl)methyl]amino} sulfonyl)-1*H*-indole-2-carboxamide;

5-chloro-3-{{(2,3-dihydro-1,4-benzodioxin-2-ylmethyl) amino}sulfonyl}-1H-indole-2-carboxamide;

5-bromo-3-{{(3-ethoxypropyl) amino}sulfonyl}-1H-indole-2-carboxamide;

3-{{([2-(aminocarbonyl)-5-bromo-1H-indol-3-yl]sulfonyl) amino) methyl]-1-benzylpyrrolidine;

5-bromo-3-{{([1-benzylpyrrolidin-3-yl)methyl]amino}sulfonyl)-1H-indole-2-carboxamide;

5-bromo-3-{{(3-pyridin-3-ylpropyl)amino}sulfonyl}-1H-indole-2-carboxamide;

1-[2-{{([2-(aminocarbonyl)-5-bromo-1H-indol-3-yl]sulfonyl) amino)ethyl]-4-phenylpiperidine;

5-bromo-3-{{(3-cyclohexylpropyl)amino}sulfonyl}-1H-indole-2-carboxamide;

5-bromo-3-{{(4,4-diphenylbutyl)amino}sulfonyl}-1H-indole-2-carboxamide;

5-bromo-3-{{(3-butoxypropyl)amino}sulfonyl}-1H-indole-2-carboxamide;

5-bromo-3-{{(6,7,8,9-tetrahydro-5H-benzo[a][7]annulen-7-ylmethyl)amino}sulfonyl}-1H-indole-2-carboxamide;

5-bromo-3-{{[3-(3,5-dimethyl-1H-pyrazol-1-yl)propyl]amino}sulfonyl)-1H-indole-2-carboxamide;

5-bromo-3-{{[3-(4-tert-butoxyphenyl)propyl]amino}sulfonyl)-1H-indole-2-carboxamide;

5-bromo-3-{{[4-(4-tert-butoxyphenyl)butyl]amino}sulfonyl)-1H-indole-2-carboxamide;

5-bromo-3-{{(2-methoxy-1-methylethyl)amino}sulfonyl}-1H-indole-2-carboxamide;

5-bromo-3-{{(4-phenylbutyl)amino}sulfonyl}-1H-indole-2-carboxamide;

5-bromo-3-{{[2-[(2,6-dichlorobenzyl)thio]ethyl]amino}sulfonyl)-1H-indole-2-carboxamide;

5-bromo-3-{{[2-(tert-butylthio)ethyl]amino}sulfonyl)-1H-indole-2-carboxamide;


5-bromo-3-{{[6-[(4-chlorobenzyl)amino]-6-oxohexyl]amino}sulfonyl)-1H-indole-2-carboxamide;




or a pharmaceutically acceptable salt or stereoisomer thereof.

5. (Original) The compound according to Claim 4, that is selected from:


5-Chloro-3- {[ethyl(methyl)amino]sulfonyl}-1*H*-indole-2-carboxamide




(±)-5-Bromo-3- {[methyl(tetrahydrofuran-3-yl)amino]sulfonyl}-1*H*-indole-2-carboxamide




3-([2-(Aminosulfonyl)ethyl]amino)sulfonyl)-5-bromo-1*H*-indole-2-carboxamide




5-Bromo-3- {[2- {[4-methoxyphenyl]sulfonyl]amino}ethyl]amino]sulfonyl}-1*H*-indole-2-carboxamide




5-bromo-3-[[3-(butoxypropyl)amino]sulfonyl]-1H-indole-2-carboxamide



5-bromo-3-([3-(4-tert-butoxyphenyl)propyl]amino)sulfonyl)-1H-indole-2-carboxamide



5-chloro-3-({[2-(3-phenyl-1*H*-1,2,4-triazol-5-yl)ethyl]amino}sulfonyl)-1*H*-indole-2-carboxamide



or a pharmaceutically acceptable salt or stereoisomer thereof.

6. (Original) A pharmaceutical composition which is comprised of a compound in accordance with Claim 1 and a pharmaceutically acceptable carrier.

7. (Withdrawn by Examiner) A method of modulating the catalytic activity of protein kinases in a mammal in need thereof comprising contacting the protein kinase with a compound of Claim 1.

8. (Withdrawn by Examiner) The method of Claim 7 wherein the protein kinase is an RTK.

9. (Withdrawn by Examiner) The method of Claim 8, wherein the RTK is selected from IR, IGF-1R and IRR.

10. (Withdrawn by Examiner) A method of treating or preventing a PK-related disorder in a mammal in need thereof comprising administering to said mammal a therapeutically effective amount of a compound of Claim 1.

11. (Withdrawn by Examiner) A method of Claim 10, wherein the PK-related disorder is an IGF-1R-related disorder selected from:

- 1) cancer,
- 2) diabetes,
- 3) an autoimmune disorder,
- 4) a hyperproliferation disorder,
- 5) aging,
- 6) acromegaly, and
- 7) Crohn's disease.

12. (Withdrawn by Examiner) A method of treating cancer in a mammal in need of such treatment comprising administering to said mammal a therapeutically effective amount of a compound of Claim 1.

13. (Withdrawn by Examiner) A method of treating retinal vascularization comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Claim 1.

14. (Withdrawn by Examiner) A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with a second compound selected from:

- 1) an estrogen receptor modulator,
- 2) an androgen receptor modulator,
- 3) retinoid receptor modulator,
- 4) a cytotoxic agent,
- 5) an antiproliferative agent,
- 6) a prenyl-protein transferase inhibitor,
- 7) an HMG-CoA reductase inhibitor,
- 8) an HIV protease inhibitor,
- 9) a reverse transcriptase inhibitor, and
- 10) an angiogenesis inhibitor.

15. (Withdrawn by Examiner) The method of Claim 14, wherein the second compound is an estrogen receptor modulator selected from tamoxifen and raloxifene.

16. (Withdrawn by Examiner) A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with radiation therapy.

17. (Withdrawn by Examiner) The method of Claim 16 wherein radiation therapy is also administered.

18. (Withdrawn by Examiner) A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 and paclitaxel or trastuzumab.

19. (Withdrawn by Examiner) A method of treating or preventing cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 and a GPIIb/IIIa antagonist.

20. (Previously Canceled)

21. (Previously Canceled)
22. (Previously Canceled)
23. (Previously Canceled)